987P - Whole abdominopelvic radiotherapy (WAPRT) using intensity modulated arc therapy (IMAT) as palliation for platinum-resistant ovarian cancer

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Ovarian Cancer
Surgery and/or Radiotherapy of Cancer
Presenter Amin Philip Makar
Authors A.P. Makar
  • Gynaecologic Oncology, University of Ghent, 9000 - Gent/BE

Abstract

Background and aims

To asses the palliative effect of WAPRT using IMAT for patients with chemotherapy-resistant ovarian cancer.

Methods

Forty-two patients were treated (33Gy; 22 daily fractions). At referral, median [range] age and Karnofsky performance score (KPS) was 59y [31 -76] and 80 [40-90]. Disease-related symptoms were: intestinal (sub)-obstruction (n = 22), minor gastro-intestinal symptoms (n = 2), pain (n = 20), ascites (n = 11), and vaginal bleeding (n = 2). Median [range] CA125 serum level was 421 U/ml [6-13796]. All patients were heavily pre-treated. The actuarial overall survival (OS) and abdominal progression free survival (aPFS) were calculated from the start, response duration from the end of treatment.

Results

Response rates (completed treatments; n = 30): The median [range] response duration (all symptoms) was 16 weeks [0-139]. For the whole population median [range] OS and aPFS was 4 months [0-32] and 11 weeks [0-142]. For those patients who completed treatment median [range] OS and aPFS was 8 months [2-32] and 17 weeks [4-142]. Patients with a KPS ≥70 ended the treatment significantly more (p < 0.001), had a better OS (8 vs. 1 month; P < 0.05), aPFS (18 vs 3 weeks; p < 0.001) and response duration (22 vs 5 weeks p < 0.001). 4)

Conclusion

WAPRT offers important palliation for peritoneal metastasized /platinum resistant ovarian cancer patients. It can resolve intestinal obstruction for a substantial period. Carefull patient selection is mandatory (KPS ≥ 70).

Disclosure

All authors have declared no conflicts of interest.